Mbiomics Secures $30M to Advance Microbiome Therapy for Melanoma

Mbiomics, a biotechnology company focused on harnessing the microbiome to fight cancer, has raised $30 million in a Series A funding round. The company is developing a live bacterial product designed to treat melanoma, with a Phase 1b clinical trial planned for 2027. This investment marks a significant step forward in the emerging field of microbiome-based cancer therapies.